Tirzepatide provides dose-dependent weight loss of 5-21%, reduces appetite, and improves lipids across clinical trials | Research

The takeaway

Tirzepatide achieves 5-20.9% weight loss over 72 weeks with dose-dependent efficacy, significant HbA1c reductions (20-28 mmol/mol), favorable lipid effects, and manageable GI side effects with 4-10% discontinuation rates.

Up to 20.9% weight loss
Tirzepatide achieves remarkable dose-dependent weight reduction with comprehensive metabolic improvement in glucose, lipids, and appetite

What the researchers found

Weight loss: 5-20.9% (dose-dependent, 72 weeks). Fat mass primary driver. HbA1c: -20.4 to -28.2 mmol/mol. Reduced appetite, increased satiety. Improved cholesterol, LDL, triglycerides, HDL. GI AEs at higher doses; 4-10% discontinuation.

Why it matters

Understanding tirzepatide's full metabolic profile—beyond weight loss—helps clinicians and patients make informed treatment decisions and manage expectations.

How the study worked

Narrative review of tirzepatide clinical trial data covering weight loss, body composition, appetite, glycemic control, and lipid effects.

What this study cannot tell us

Narrative review. Trials had specific populations. Long-term (>72 weeks) data limited. Body composition data from limited studies. Weight regain after discontinuation not comprehensively covered.

How to read the evidence

Narrative review of phase 3 clinical trial data. Strong evidence base from SURPASS and SURMOUNT programs.

When this study was published

Published in 2025.

The bigger picture

Tirzepatide's dual GLP-1/GIP mechanism produces comprehensive metabolic improvement—weight, glucose, lipids, and appetite—making it one of the most versatile metabolic drugs ever developed.

Questions still open

How does tirzepatide's body composition effect compare to semaglutide?
Will the metabolic benefits persist long-term?
Which dose offers the best efficacy-tolerability balance?

Common questions

How much weight can tirzepatide help me lose?

Clinical trials show 5-20.9% body weight loss depending on the dose, over about 72 weeks. Higher doses (15 mg) produce the most weight loss. The weight lost is primarily fat mass, and the drug also reduces appetite and increases feelings of fullness.

Does tirzepatide improve anything besides weight?

Yes—substantially. It reduces blood sugar (HbA1c), lowers bad cholesterol (LDL) and triglycerides, raises good cholesterol (HDL), and decreases appetite. This makes it a comprehensive metabolic treatment, not just a weight loss drug.

Read the original research

The promise of tirzepatide: A narrative review of metabolic benefits.

Primary care diabetes, 19(3), 229-237

View on PubMed ↗Publisher’s paper ↗

Citation

Sokary, Sara; Bawadi, Hiba. (2025). The promise of tirzepatide: A narrative review of metabolic benefits.. Primary care diabetes, 19(3), 229-237. https://doi.org/10.1016/j.pcd.2025.03.008